Dr. Jonathan A. Coleman Profile

Dr. Jonathan A. Coleman

at Memorial Sloan-Kettering Cancer Ctr Medical Library

SPIE Involvement:

Author

Proceedings Article | 5 March 2021 Presentation + Paper

An intravenous fluorophore for enhanced intraoperative nerve visualization

Andrew Silagy, Lucas Dean, Erica Levine, Kathleen Deardorff, Guangbin Yang, Mohammad Marzabadi, Zhong-Ke Yao, Ouathek Ouerfelli, Walter Greenblatt, Jonathan Coleman, Peter Scardino, Béla Denes, Vincent Laudone, Timothy Donahue

Proceedings Volume 11625, 116250N (2021) https://doi.org/10.1117/12.2577710

KEYWORDS: Visualization, Nerve, Visual process modeling, Tissue optics, Surgery, Luminescence, Laparoscopy, Injuries, Abdomen

Read Abstract +

Proceedings Article | 14 August 2019 Presentation

Clinical trial experience with Tookad soluble vascular targeted photodynamic therapy for genitourinary cancers at Memorial Sloan Ketterin (Conference Presentation)

Jonathan Coleman

Proceedings Volume 11070, 1107033 (2019) https://doi.org/10.1117/12.2531720

Read Abstract +

Proceedings Article | 14 August 2019 Presentation

Vascular targeted photodynamic therapy with Tookad: from local ablation to systemic cancer treatment (Conference Presentation)

Avigdor Scherz, Lilach Agemi, Dina Preise, Rachel Elmoalem-Hamri, Jonathan Coleman

Proceedings Volume 11070, 1107035 (2019) https://doi.org/10.1117/12.2527629

KEYWORDS: Cancer, Photodynamic therapy, Oncology, Therapeutics, Tumors, Modulation, Prostate cancer, Esophagus, Prostate, Genomics

Read Abstract +

Vascular targeted photodynamic therapy with TOOKAD-from local ablation to systemic cancer treatment Background: Local therapies that allow for safe ablation of primary lesions and trigger anti-tumor immunity with minimal side effects, may be particularly effective in management of early-stage cancer. Vascular-targeted photodynamic therapy (VTP) with TOOKAD®, recently granted EMA approval as a first-line treatment for localized prostate cancer, has been shown by us to also trigger anti-tumor immunity. Our recent preclinical and current clinical studies aim to test the hypothesis that synchronizing TOOKAD®VTP with immune-modulation that attenuates the pro-tumor immunity, will result in systemic micrometastases annihilation and a high cure rate. Methods: 4T1-Luc, adenosquamous JA and Met-Lu cells were orthotopically grafted in the mammary pad, esophagus and prostate of immune-competent mice and rats, respectively. Seven days postgrafting, tumors were treated with TOOKAD®VTP, with or without immune-modulators. Immune profiles were examined by 10-X genomics, FACS analysis and immunohistochemistry. Animal survival and lung and lower abdomen metastases counts were followed up for 3 months. Clinical protocols were composed based on the preclinical data and utilized in the clinical studies that will be described in other lectures of this session. Results: TOOKAD®VTP triggered anti-tumor immunity sufficient to achieve 60-90% cure in various cancer models. However, primary lesion annihilation did not prevent disease progression in the more aggressive cancers such as 4T1-Luc breast cancer. TOOKAD®VTP synchronized with metronomic administration of immune-modulators was associated with a 60-90% disease-free animals and resistance to re-challenge. The rate of success was highly pending on the exact synchronization of the immune modulating agents with the VTP timing. The required modulators match the deciphered immune profiles. This combined immuno-VTP therapy concept has been translated to clinical trials currently ongoing at Memorial Sloan Kettering Cancer Center. Conclusion: Application of TOOKAD®VTP to localized tumors combined with immune modulation appears to provide novel means to treat early disseminated cancers.

Proceedings Article | 11 April 2002 Paper

Ultrasound characterization of the infertile male testis with rf power spectrum analysis

Jonathan Coleman, Ronald Silverman, Mark Rondeau, D. Coleman, Peter Schlegel

Proceedings Volume 4687, (2002) https://doi.org/10.1117/12.462148

KEYWORDS: Tissues, Ultrasonography, Testis, Spectrum analysis, Biopsy, Control systems, Diagnostics, Transducers, Pathology, Biological research

Read Abstract +

Conference Committee Involvement (1)

17th International Photodynamic Association World Congress

28 June 2019 | Cambridge, Massachusetts, United States

Keywords/Phrases

Search In:

Publication Years